References
- Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, Wu Y, Sow SO, Sur D, Breiman RF, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet. 2013;382:209–222. doi:https://doi.org/10.1016/S0140-6736(13)60844-2.
- Sow SO, Muhsen K, Nasrin D, Blackwelder WC, Wu Y, Farag TH, Panchalingam S, Sur D, Zaidi AK, Faruque AS, et al. The burden of Cryptosporidium diarrheal disease among children < 24 months of age in moderate/high mortality regions of sub-saharan Africa and South Asia, utilizing data from the Global Enteric Multicenter Study (GEMS). PLoS Negl Trop Dis. 2016;10:e0004729. doi:https://doi.org/10.1371/journal.pntd.0004729.
- Molbak K, Andersen M, Aaby P, Hojlyng N, Jakobsen M, Sodemann M, Da Silva AP. Cryptosporidium infection in infancy as a cause of malnutrition: a community study from Guinea-Bissau, west Africa. Am J Clin Nutr. 1997;65:149–152. doi:https://doi.org/10.1093/ajcn/65.1.149.
- Guerrant DI, Moore SR, Lima AA, Patrick PD, Schorling JB, Guerrant RL. Association of early childhood diarrhea and cryptosporidiosis with impaired physical fitness and cognitive function four-seven years later in a poor urban community in northeast Brazil. Am J Trop Med Hyg. 1999;61:707–713.
- Tumwine JK, Kekitiinwa A, Nabukeera N, Akiyoshi DE, Rich SM, Widmer G, Feng X, Tzipori S. Cryptosporidium parvum in children with diarrhea in Mulago Hospital, Kampala, Uganda. Am J Trop Med Hyg. 2003;68:710–715.
- Abubakar I, Aliyu SH, Arumugam C, Hunter PR, Usman NK. Prevention and treatment of cryptosporidiosis in immunocompromised patients. Cochrane Database Syst Rev. 2007;CD004932. DOI:https://doi.org/10.1002/14651858.CD004932.pub2.
- Bessoff K, Spangenberg T, Foderaro JE, Jumani RS, Ward GE, Huston CD. Identification of Cryptosporidium parvum active chemical series by Repurposing the open access malaria box. Antimicrob Agents Chemother. 2014;58:2731–2739. doi:https://doi.org/10.1128/AAC.02641-13.
- Kumar H, Singh VB, Meena BL, Agrawal J, Beniwal S, Swami T. Pulmonary cryptosporidiosis in an immunocompetent host treated successfully with nitazoxanide. Lung India. 2016;33:69–71. doi:https://doi.org/10.4103/0970-2113.173085.
- Mondal D, Minak J, Alam M, Liu Y, Dai J, Korpe P, Liu L, Haque R, Petri WA Jr. Contribution of enteric infection, altered intestinal barrier function, and maternal malnutrition to infant malnutrition in Bangladesh. Clin Infect Dis. 2012;54:185–192. doi:https://doi.org/10.1093/cid/cir807.
- Hong DK, Wong CJ, Gutierrez K. Severe cryptosporidiosis in a seven-year-old renal transplant recipient: case report and review of the literature. Pediatr Transplant. 2007;11:94–100. doi:https://doi.org/10.1111/j.1399-3046.2006.00593.x.
- Rossignol JF. Cryptosporidium and Giardia: treatment options and prospects for new drugs. Exp Parasitol. 2010;124:45–53. doi:https://doi.org/10.1016/j.exppara.2009.07.005.
- Amadi B, Mwiya M, Musuku J, Watuka A, Sianongo S, Ayoub A, Kelly P. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet. 2002;360:1375–1380. doi:https://doi.org/10.1016/S0140-6736(02)11401-2.
- Rossignol JF, Hidalgo H, Feregrino M, Higuera F, Gomez WH, Romero JL, Padierna J, Geyne A, Ayers MS. A double-’blind’ placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans R Soc Trop Med Hyg. 1998;92:663–666.
- Bessoff K, Sateriale A, Lee KK, Huston CD. Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth. Antimicrob Agents Chemother. 2013;57:1804–1814. doi:https://doi.org/10.1128/AAC.02460-12.
- Kuzmuk KN, Schook LB. Pigs as a Model for Biomedical Sciences. Rothschild MF, Ruvinsky A, eds. The Genetics of the Pig: CAB International; 2011.UK: Wallingford.
- Patterson JK, Lei XG, Miller DD. The pig as an experimental model for elucidating the mechanisms governing dietary influence on mineral absorption. Exp Biol Med (Maywood). 2008;233:651–664. doi:https://doi.org/10.3181/0709-MR-262.
- Stokes CR, Bailey M, Haverson K, Harris C, Jones P, Inman C, Pié S, Oswald IP, Williams BA, Akkermans ADL, et al. Postnatal development of intestinal immune system in piglets: implications for the process of weaning. Anim Res. 2004;53:325-34:DOI:https://doi.org/10.1051/animres:2004020.
- Saif LJ, Ward LA, Yuan L, Rosen BI, To TL. The gnotobiotic piglet as a model for studies of disease pathogenesis and immunity to human rotaviruses. Arch Virol Suppl. 1996;12:153–161.
- Wochtl B, Gunzer F, Gerner W, Gasse H, Koch M, Bago Z, Ganter M, Weissenbock H, Dinhopl N, Coldewey SM, et al. Comparison of clinical and immunological findings in gnotobiotic piglets infected with Escherichia coli O104: h4outbreak strain and EHEC O157:H7. Gut Pathog. 2017;9:30. doi:https://doi.org/10.1186/s13099-017-0179-8.
- Tzipori S, Wachsmuth IK, Chapman C, Birden R, Brittingham J, Jackson C, Hogg J. The pathogenesis of hemorrhagic colitis caused by Escherichia coli O157: h7in gnotobiotic piglets. J Infect Dis. 1986;154:712–716.
- Baker DR, Moxley RA, Francis DH. Variation in virulence in the gnotobiotic pig model of O157: h7Escherichia coli strains of bovine and human origin. Adv Exp Med Biol. 1997;412:53–58.
- Jeong KI, Zhang Q, Nunnari J, Tzipori S. A piglet model of acute gastroenteritis induced by Shigella dysenteriae Type 1. J Infect Dis. 2010;201:903–911. doi:https://doi.org/10.1086/650995.
- Steele J, Feng H, Parry N, Tzipori S. Piglet models of acute or chronic Clostridium difficile illness. J Infect Dis. 2010;201:428–434. doi:https://doi.org/10.1086/649799.
- Lee S, Harwood M, Girouard D, Meyers MJ, Campbell MA, Beamer G, Tzipori S. The therapeutic efficacy of azithromycin and nitazoxanide in the acute pig model of Cryptosporidium hominis. PLoS One. 2017;12:e0185906. doi:https://doi.org/10.1371/journal.pone.0185906.
- Tzipori S, Rand W, Griffiths J, Widmer G, Crabb J. Evaluation of an animal model system for cryptosporidiosis: therapeutic efficacy of paromomycin and hyperimmune bovine colostrum-immunoglobulin. Clin Diagn Lab Immunol. 1994;1:450–463.
- Akiyoshi DE, Feng X, Buckholt MA, Widmer G, Tzipori S. Genetic analysis of a Cryptosporidium parvum human genotype 1 isolate passaged through different host species. Infect Immun. 2002;70:5670–5675.
- Sponseller JK, Griffiths JK, Tzipori S. The evolution of respiratory Cryptosporidiosis: evidence for transmission by inhalation. Clin Microbiol Rev. 2014;27:575–586. doi:https://doi.org/10.1128/CMR.00115-13.
- Tzipori S, Widmer G. A hundred-year retrospective on cryptosporidiosis. Trends Parasitol. 2008;24:184–189. doi:https://doi.org/10.1016/j.pt.2008.01.002.
- Bancroft GJ, Kelly JP, McDonald V. Models of innate immunity and opportunistic infection in the SCID mouse. Res Immunol. 1994;145:344–347.
- Pereira SJ, Ramirez NE, Xiao L, Ward LA. Pathogenesis of human and bovine Cryptosporidium parvum in gnotobiotic pigs. J Infect Dis. 2002;186:715–718. doi:https://doi.org/10.1086/342296.
- Akiyoshi DE, Mor S, Tzipori S. Rapid displacement of Cryptosporidium parvum type 1 by type 2 in mixed infections in piglets. Infect Immun. 2003;71:5765–5771.
- Akiyoshi DE, Dilo J, Pearson C, Chapman S, Tumwine J, Tzipori S. Characterization of Cryptosporidium meleagridis of human origin passaged through different host species. Infect Immun. 2003;71:1828–1832.
- Tumwine JK, Kekitiinwa A, Bakeera-Kitaka S, Ndeezi G, Downing R, Feng X, Akiyoshi DE, Tzipori S. Cryptosporidiosis and microsporidiosis in ugandan children with persistent diarrhea with and without concurrent infection with the human immunodeficiency virus. Am J Trop Med Hyg. 2005;73:921–925.
- Xu P, Widmer G, Wang Y, Ozaki LS, Alves JM, Serrano MG, Puiu D, Manque P, Akiyoshi D, Mackey AJ, et al. The genome of Cryptosporidium hominis. Nature. 2004;431:1107–1112. doi:https://doi.org/10.1038/nature02977.
- Ifeonu OO, Chibucos M, Orvis J, Su Q, Elwin K, Guo F, Zhang H, Xiao L, Sun M, Chalmers RM, et al. Annotated draft genome sequences of three species of Cryptosporidium: C. meleagridis isolate UKMEL1, C. baileyi isolate TAMU-09Q1, and C. hominis isolates TU502_2012 and UKH1. Pathog Dis. 2016; DOI:https://doi.org/10.1093/femspd/ftw080.
- Chappell CL, Okhuysen PC, Langer-Curry R, Widmer G, Akiyoshi DE, Tanriverdi S, Tzipori S. Cryptosporidium hominis: experimental challenge of healthy adults. Am J Trop Med Hyg. 2006;75:851–857.
- Morada M, Lee S, Gunther-Cummins L, Weiss LM, Widmer G, Tzipori S, Yarlett N. Continuous culture of Cryptosporidium parvum using hollow fiber technology. Int J Parasitol. 2016;46:21–29. doi:https://doi.org/10.1016/j.ijpara.2015.07.006.
- Lee S, Ginese M, Beamer G, Danz HR, Girouard DJ, Chapman-Bonofiglio SP, Lee M, Hulverson MA, Choi R, Whitman GR, et al. Therapeutic efficacy of bumped kinase inhibitor 1369 in the acute pig model of Cryptosporidium hominis. Antimicrob Agents Chemother. 2018; DOI:https://doi.org/10.1128/AAC.00147-18.
- Theodos CM, Griffiths JK, D’Onfro J, Fairfield A, Tzipori S. Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models. Antimicrob Agents Chemother. 1998;42:1959–1965.